Insider transactions

William Jl Rieflin

CIK 1182471 · Executive Chairman · last filed 2026-06-12

William Jl Rieflin is an Executive Chairman who has filed 54 SEC Form 4 insider transactions across 5 companies since 2007. The most recent filing, for LYEL, was dated Jun 12, 2026. Across all open-market trades the lifetime net is +$275.2K, making them a net buyer over the disclosed history.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure
$0
Companies
5
Total Filings
54
Lifetime Open-Market Net
$275.2K

Charts

Trading activity, where the exposure sits, and each trade against the stock price.

Filer Profile

Reported Address
NGM BIOPHARMACEUTICALS, INC.
333 OYSTER POINT BLVD.
SOUTH SAN FRANCISCO, CA 94080
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
LYEL Director — $9.26 — $0 6 2026-06-12
RAPT Therapeutics, Inc. (RAPT) Delisted Director 11,840 $58.01 $686.8K $258.2K 11 2024-05-23
NGM BIOPHARMACEUTICALS INC (NGM) Delisted Executive Chairman 0 $1.54 $0 $0 6 2024-04-08
XENOPORT INC (XNPT) Delisted Director 0 — — $17.0K 24 2016-07-06
Anacor Pharmaceuticals, Inc. (ANAC) Delisted Director 0 $10.19 $0 $0 7 2016-06-24

Recent Filings

54 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-12 LYEL Grant (A) — $0 EDGAR
2025-05-19 LYEL Grant (A) — $0 EDGAR
2024-06-17 LYEL Grant (A) — $0 EDGAR
2024-05-23 RAPT Therapeutics, Inc. (RAPT) Delisted Grant (A) — $0 EDGAR
2024-04-08 NGM BIOPHARMACEUTICALS INC (NGM) Delisted Mixed −2,774,340 $0 EDGAR
2024-04-01 RAPT Therapeutics, Inc. (RAPT) Delisted Grant (A) — $0 EDGAR
2023-09-08 LYEL Grant (A) — $0 EDGAR
2023-06-20 LYEL Grant (A) — $0 EDGAR
2023-05-25 RAPT Therapeutics, Inc. (RAPT) Delisted Grant (A) — $0 EDGAR
2023-05-12 NGM BIOPHARMACEUTICALS INC (NGM) Delisted Grant (A) — $0 EDGAR
Showing 1–10 of 54
Page 1 of 6
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.